Weaning of proton pump inhibitors in patients with suspected laryngopharyngeal reflux disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  The Laryngoscope

• Publication date

  2018-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/lary.26696PMID 28730666
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.

  2016cited by this paper
• Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.

  2016cited by this paper
• Use of proton pump inhibitors is associated with fractures in young adults: a population-based study

  2015cited by this paper
• Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population

  2015cited by this paper
• Public Transportation and Tuberculosis Transmission in a High Incidence Setting

  2015cited by this paper
• Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea.

  2014cited by this paper
• A Proton Pump Inhibitor’s Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study

  2014cited by this paper
• Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients

  2014cited by this paper
• Proton pump inhibitor use represents an independent risk factor for myocardial infarction.

  2014cited by this paper
• Laryngopharyngeal Reflux: Diagnosis, Treatment, and Latest Research

  2013cited by this paper
• The prevalence of laryngopharyngeal reflux in the English population

  2012cited by this paper
• Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse

  2010cited by this paper
• Meta‐analysis: the effects of placebo treatment on gastro‐oesophageal reflux disease

  2010cited by this paper
• Discontinuation of proton pump inhibitors in patients on long‐term therapy: a double‐blind, placebo‐controlled trial

  2006cited by this paper
• Author Index to Abstracts

  2006cited by this paper
• Treatment of Chronic Throat Symptoms with PPIs Should Be Preceded by pH Monitoring

  2006influential reference
• Body-mass index and symptoms of gastroesophageal reflux in women.

  2006cited by this paper
• The role of pH monitoring in extraesophageal gastroesophageal reflux disease.

  2005cited by this paper
• Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.

  2004cited by this paper
• Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association.

  2003cited by this paper
• Intrapharyngeal Distribution of Gastric Acid Refluxate

  2003cited by this paper
• Step-down management of gastroesophageal reflux disease.

  2003influential reference
• Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project.

  2003cited by this paper
• Validity and reliability of the reflux symptom index (RSI).

  2002cited by this paper
• Esophageal Motor Function in Laryngopharyngeal Reflux is Superior to That in Classic Gastroesophageal Reflux Disease

  2001influential reference
• Problems related to acid rebound and tachyphylaxis.

  2001cited by this paper
• Rebound acid hypersecretion after omeprazole is a prolonged phenomenon

  2000cited by this paper
• Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux.

  2000cited by this paper
• Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.

  1998cited by this paper
• Reproducibility of proximal probe pH parameters in 24-hour ambulatory esophageal pH monitoring.

  1997influential reference
• Safety issues relating to long‐term treatment with histamine H2‐receptor antagonists

  1993cited by this paper
• Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients.

  1990cited by this paper
• Nocturnal doses of H2 receptor antagonists for duodenal ulcer.

  1985cited by this paper
• Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.

  1983cited by this paper
• Letter: Indomethacin and closure of the ductus arteriosus.

  1975cited by this paper
• Inhibition of nocturnal acid secretion in duodenal ulcer by one oral dose of metiamide.

  1974cited by this paper

• DIAGNOSTIC ACCURACY OF SALIVARY PEPSIN EVALUATION FOR THE DIAGNOSIS OF LARYNGOPHARYNGEAL REFLUX IN PATIENTS WITH LARYNGOPHARYNGEAL CANCER

  2025cites this paper
• European clinical practice guideline: managing and treating laryngopharyngeal reflux disease

  2024cites this paper
• A Meta-analysis of PPIs Plus Alginate Versus PPIs Alone for the Treatment of GERD.

  2024cites this paper
• Personalized Treatments Based on Laryngopharyngeal Reflux Patient Profiles: A Narrative Review

  2023cites this paper
• Chinese consensus on multidisciplinary diagnosis and treatment of gastroesophageal reflux disease 2022 gastroesophageal reflux disease committee, China international exchange and Promotive Association for medical and health care

  2023cites this paper
• Treating and Managing Laryngopharyngeal Reflux Disease in the Over 65s: Evidence to Date

  2022cites this paper
• Evaluation of Oropharyngeal pH-Monitoring in the Assessment of Laryngopharyngeal Reflux

  2021cites this paper
• Chronic Course, Weaning, and Awareness of Patients With Reflux Toward Proton Pump Inhibitor Therapy.

  2021cites this paper
• Retrospective analysis of a pilot pharmacist‐led hospice deprescribing program initiative

  2021cites this paper
• Laryngopharyngeal Reflux Disease: Diagnosis and Treatment in 2021

  2021cites this paper
• What is the truth about proton pump inhibitors?

  2020cites this paper
• Is empirical treatment a reasonable strategy for laryngopharyngeal reflux? A contemporary review

  2020cites this paper
• Reflux finding score and reflux symptom index as potential predictors for proton pump inhibitor response in globus pharyngeus patients: A prospective study.

  2020cites this paper
• H+/K+ATPase Expression in the Larynx of Laryngopharyngeal Reflux and Laryngeal Cancer Patients

  2020cites this paper
• Assessment and Diagnostic Accuracy Evaluation of the Reflux Symptom Index (RSI) Scale: Psychometric Properties using Optimal Scaling Techniques

  2020cites this paper
• Laryngopharyngeal reflux image quantization and analysis of its severity

  2020cites this paper
• Integrative East-West Medicine for Reflux Disease

  2019cites this paper
• Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic.

  2019cites this paper
• Efficacy of three proton‐pump inhibitor therapeutic strategies on laryngopharyngeal reflux disease; a prospective randomized double‐blind study

  2019cites this paper
• Laryngopharyngeal Reflux: Current Concepts on Etiology and Pathophysiology and Its Role in Dysphagia

  2018cites this paper
• Laryngopharyngeal reflux disease: clinical presentation, diagnosis and therapeutic challenges in 2018

  2018cites this paper
• Proton pump inhibitors: Review of reported risks and controversies

  2018cites this paper
• Associations between Community-Acquired Pneumonia and Proton Pump Inhibitors in the Laryngeal/Voice-Disordered Population

  2018cites this paper
• Questionnaire Diagnosis of Airways Reflux

  2018cites this paper